60 Degrees Pharmaceuticals (SXTP) Total Liabilities (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Total Liabilities of $2.0 million for Q1 2026, up 3.59% year-over-year from $1.9 million in Q1 2025, and up 1.61% quarter-over-quarter from $2.0 million in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Total Liabilities (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Total Liabilities for 5 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 3.59% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 3.59% YoY), while the FY2025 annual figure was $2.0 million, up 10.11% from the prior year.
- Total Liabilities climbed to $2.0 million in Q1 2026 per SXTP's latest filing, from $2.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $30.2 million in Q2 2023 and bottomed at $1.3 million in Q1 2024.
- Historically, Total Liabilities has averaged $5.9 million across 5 years, with a median of $2.0 million in 2025.
- Annual changes were most pronounced in 2024 — Total Liabilities slumped 95.48% — and 2025, when it jumped 60.65%.
- 60 Degrees Pharmaceuticals' Total Liabilities stood at $25.4 million in 2022, then plunged by 88.27% to $3.0 million in 2023, then sank by 39.57% to $1.8 million in 2024, then grew by 10.11% to $2.0 million in 2025, then gained by 1.61% to $2.0 million in 2026.
- Business Quant data shows SXTP's Total Liabilities at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 10.03 Bn |
| 10 | 60 Degrees Pharmaceuticals | 3.01 Mn | 1.99 Mn | 56,798.00 | 1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.02 Mn |
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 2.99 Mn |
| Sep 30, 2023 | 2.63 Mn |
| Jun 30, 2023 | 30.24 Mn |
| Dec 31, 2022 | 25.45 Mn |